IL1B and autoinflammatory syndrome: Anakinra, a recombinant human interleukin-1 receptor antagonist (IL-1Ra), that inhibits the binding of IL-1 to its receptors, has displayed tremendous efficacy on controlling disease flares and inflammation-mediated organ damage in autoinflammatory syndromes [1, 2].